U.S. Markets open in 9 hrs 1 mins

Valeant Pharmaceuticals International, Inc. (VRX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.34+0.19 (+1.34%)
At close: 4:01PM EDT
People also watch
AGNGILDENDPFITTWTR
Full screen
Previous Close14.15
Open14.30
Bid0.00 x 0
Ask0.00 x 0
Day's Range14.22 - 14.89
52 Week Range8.31 - 32.74
Volume21,846,271
Avg. Volume19,097,893
Market Cap4.99B
Beta-1.07
PE Ratio (TTM)-3.54
EPS (TTM)-4.05
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2010-11-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com12 hours ago

    Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

    For his "Executive Decision" segment, Cramer again sat down with Joe Papa, chairman and CEO of Valeant

  • Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Higher Today
    InvestorPlace13 hours ago

    Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Higher Today

    The manufacturing issues that the company was facing were connected to an investigation by the U.S. Food and Drug Administration (FDA). Valeant Pharmaceuticals Intl Inc notes that the FDA is planning to give the facility a Voluntary Action Indicated VAI classification. Valeant Pharmaceuticals Intl Inc says that the VAI classification will prevent manufacturing issues that further regulator actions could have caused.

  • Barrons.com15 hours ago

    Valeant: Hard to Ignore the Positive Developments?

    Shares of Valeant Pharmaceuticals International (VRX) have tumbled 14% in August as concerns about generic drugs following Teva Pharmaceutical Industries' (TEVA) earnings sparked a specialty-pharmaceutical stock selloff. Valeant, however, is trying to make back some of those losses this week, with the stock up more than 2% today after the company announced that it was close to fixing problems at a Bausch & Lomb plant. While this might seem like a minor piece of news, it has big implications for Valeant's stock.